公开(公告)号：EP2007769B1

公开(公告)日：2011-06-15

申请号：EP07731259.3

申请日：2007-04-06

申请人： Sanofi-Aventis

发明人： COMMERCON, Alain ,  ZHANG, Jidong ,  HITTINGER, Augustin

IPC分类号： C07D493/22 ,  A61K31/357 ,  A61P35/00

CPC分类号： C07D313/04 ,  C07D321/04 ,  C07D323/04 ,  C07D493/22

摘要： The present invention relates to novel dimers of specific artemisinin derivatives, to the preparation thereof, to compositions containing them, and to their use as a medicament, in particular as anticancer agents. (I).

公开(公告)号：EP2308892A1

公开(公告)日：2011-04-13

申请号：EP09305929.3

申请日：2009-10-01

申请人： Sanofi-Aventis

发明人： Hall, Diana ,  Jimenez, Maria ,  Poussin, Carine ,  Thorens, Bernard

IPC分类号： C07K14/47 ,  C12N15/113 ,  A61P3/06

CPC分类号： C12N15/1137 ,  C12N2310/14 ,  C12N2310/531

摘要： The present invention concerns Sipa1I1, a new target involved in adipogenesis modulation. Using a siRNA approach, the inventors demonstrated that decrease in Sipa1I1 activity in preadipocytes and adipose tissue induces a decrease in adipogenesis. Thus, the present invention relates to modulators of Sipa1I1 activity as well as screening test for identification of modulators of the activity of this target, and their use, especially in pharmaceutical composition, to modulate adipogenesis and thus treat obesity and related disorders.

摘要翻译： 本发明涉及脂肪形成调节涉及的新靶标Sipa1I1。 使用siRNA方法，本发明人证实，前脂肪细胞和脂肪组织中Sipa1I1活性的降低诱导脂肪形成减少。 因此，本发明涉及Sipa1I1活性的调节剂以及用于鉴定该靶标的活性的调节剂的筛选试验，以及它们在药物组合物中的用途，以调节脂肪形成并因此治疗肥胖症和相关疾病。

公开(公告)号：EP2305822A2

公开(公告)日：2011-04-06

申请号：EP10184152.6

申请日：2001-09-06

申请人： Aventis Pharma S.A. ,  Université Louis Pasteur, U.L.P.

发明人： Nicolau, Yves

IPC分类号： C12N15/62 ,  C07K16/18 ,  C07K14/79 ,  C07K19/00 ,  C07K14/47 ,  A61K9/127 ,  A61P25/28

CPC分类号： C07K16/18 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/55555 ,  C07K14/4711 ,  C07K14/4713 ,  C07K14/79 ,  C07K2319/00 ,  C12N2799/026

摘要： The present invention generally relates to the detection, treatment or prevention of disease states. Specifically, the present invention relates to the detection, treatment or prevention of amyloidosis or amyloid-associated diseases. The present invention further comprises methods and compositions comprising therapeutic vaccines, antisera and molecular constructs, comprising expression vectors and fusion proteins encoded therein.

公开(公告)号：EP2236607A1

公开(公告)日：2010-10-06

申请号：EP09290250.1

申请日：2009-04-02

申请人： Sanofi-Aventis

发明人： Hall, Diana ,  Jimenez, Maria ,  Poussin, Carina ,  Thorens, Bernard

IPC分类号： C12N15/11 ,  A61K48/00

CPC分类号： C12N15/1137 ,  A01K2227/101 ,  A01K2267/02 ,  C12N2310/14 ,  C12N2310/531

摘要： The present invention concerns St3Gal6, a new target involved in adipogenesis modulation. Using a siRNA approach, the inventors demonstrated that decrease in St3Gal6 activity in adipose tissue induces a decrease in adipogenesis. Thus, the present invention relates to modulators of St3Gal6 activity as well as screening test for identification of modulators of the activity of this target, and their use, especially in pharmaceutical composition, to modulate adipogenesis and thus treat obesity and related disorders.

摘要翻译： 本发明涉及参与脂肪形成调节的新靶标St3Gal6。 使用siRNA方法，发明人证明脂肪组织中St3Gal6活性的降低诱导脂肪形成减少。 因此，本发明涉及St3Gal6活性的调节剂以及用于鉴定该靶标活性的调节剂的筛选试验，以及它们在药物组合物中的用途，以调节脂肪形成并因此治疗肥胖症和相关疾病。

公开(公告)号：EP1581486B1

公开(公告)日：2009-07-29

申请号：EP03779081.3

申请日：2003-09-18

申请人： Aventis Pharmaceuticals Inc.

发明人： LI, Zhuyin, Julie ,  MEHDI, Shujaath

IPC分类号： C12Q1/48

CPC分类号： C12Q1/48

摘要： Provided herein is a novel and useful method for determining whether a compound or agent decreases or inhibits the activity of a poly(ADP-ribose)-polymerase (PARP).

公开(公告)号：EP1687642B1

公开(公告)日：2009-01-14

申请号：EP04790957.7

申请日：2004-10-07

申请人： CENTELION ,  Aventis Pharmaceuticals Inc.

发明人： NESBIT, Mark ,  SPADA, Alfred, P. ,  HE, Wei ,  MYERS, Michael, R.

IPC分类号： G01N33/74 ,  G01N33/50

CPC分类号： A61K31/498 ,  G01N33/5011 ,  G01N2333/71

摘要： This invention is directed to potent inhibitors of protein tyrosine kinase alone or in synergistic combination with antiangiogenic or chemotherapeutic agents for the abrogation of mature vasculature within chemotherapeutic refractory tumors, pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cell proliferation, and particularly treatment of brain cancer, ovarian cancer, pancreatic cancer prostate cancer, and human leukemias, such as CML, AML or ALL.

公开(公告)号：EP1905833A3

公开(公告)日：2008-07-23

申请号：EP07019306.5

申请日：2003-10-08

申请人： Aventis Pharma S.A. ,  Centre National de la Recherche Scientifique (CNRS)

发明人： Blondelet-Rouault, Marie-Hélène ,  Dominguez, Hélène ,  Darbon-Rongere, Emmanuelle ,  Gerbaud, Claude ,  Gondran, Anne ,  Karray, Fatma ,  Lacroix, Patricia ,  Oestreicher-Mermet-Bouvier, Nathalie ,  Pernodet, Jean-Luc ,  Tuphile, Karine

IPC分类号： C12N15/52 ,  C12N9/00 ,  C12N15/63 ,  C12N1/21 ,  C07K14/36 ,  C12P19/62 ,  C12R1/465

CPC分类号： C07K14/36 ,  C12N9/00 ,  C12N15/52 ,  C12P19/62 ,  C12R1/465

摘要： La présente invention concerne l'isolement et l'identification de nouveaux gènes de la voie de biosynthèse des spiramycines et de nouveaux polypeptides impliqués dans cette biosynthèse. L'invention est également relative à un procédé de production de ces polypeptides. Elle est également relative à l'utilisation de ces gènes dans le but d'augmenter les taux de production et la pureté de la spiramycine produite. L'invention concerne notamment un microorganisme produisant de la spiramycine 1 mais ne produisant pas de spiramycine II et III et l'utilisation d'un tel micoorganisme. L'invention a également trait à l'utilisation des gènes de la voie de biosynthèse des spiramycines pour la construction de mutants pouvant conduire à la synthèse de nouveaux antibiotiques ou à des formes dérivées de spiramycines. L'invention concerne encore les molécules produites grâce à l'expression de ces gènes et des compositions pharmacologiquement actives d'une molécule produite grâce à l'expression de tels gènes.

公开(公告)号：EP0763116B2

公开(公告)日：2008-04-23

申请号：EP95920972.7

申请日：1995-05-22

申请人： Aventis Pharma S.A. ,  THE UNIVERSITY OF BRITISH COLUMBIA

发明人： BENOIT, Patrick ,  DENEFLE, Patrice ,  PERRICAUDET, Michel ,  HAYDEN, Michael R. ,  LEWIS, Marion Elizabeth Suzanne

IPC分类号： C12N15/55 ,  A61K38/43 ,  C12N15/86 ,  C12N5/10 ,  A61K48/00 ,  A61K9/22 ,  C12N7/01 ,  C12R1/91

CPC分类号： A61K48/005 ,  A61K38/00 ,  A61K38/465 ,  A61K48/00 ,  A61K2039/51 ,  C12N9/20 ,  C12N15/86 ,  C12N2710/10343 ,  C12Y301/01034

摘要： Recombinant viruses comprising a heterologous DNA sequence coding for a lipase involved in lipoprotein metabolism. The invention also concerns the preparation and use in therapy of said recombinant viruses, especially for the treatment or prevention of dyslipoproteinemia-related pathologies.

公开(公告)号：EP1807697A1

公开(公告)日：2007-07-18

申请号：EP05812049.4

申请日：2005-10-24

申请人： Aventis Pharma S.A.

发明人： FOURNIER, Alain ,  BEHRENS, Ralf ,  BANDIERA, Silvio

IPC分类号： G01N33/53 ,  C12N15/65 ,  C12N15/81 ,  C12Q1/68

CPC分类号： C12N15/1055

摘要： The invention relates to a novel double hybrid system and to the uses thereof. This system provides, in particular, a tool that enables the detection of the interruption of a protein-protein interaction. The developed system uses transcription interference as a mechanism for detecting a breaking up of interacting protein pairs. The developed double hybrid system can be applied to the screening of molecules enabling the detection of molecules breaking up a protein-protein interaction as well as enabling the identification of alleles lacking in the interaction of proteins involved in the protein-protein interactions.

公开(公告)号：EP1778860A1

公开(公告)日：2007-05-02

申请号：EP05781699.3

申请日：2005-07-28

申请人： Aventis Pharmaceuticals Inc.

发明人： CAO, Yang ,  SABOL, Jeffrey, S. ,  AYERS, Stephen

IPC分类号： C12Q1/533 ,  G01N33/573 ,  G01N33/88

CPC分类号： G01N33/5094 ,  G01N33/5008 ,  G01N33/5014 ,  G01N33/5047 ,  G01N33/88

摘要： The present invention relates to a novel and useful method for assaying compounds and agents for their ability to decrease or inhibit the activity of hematopoietic prostaglandin D2 synthase (hPGDS). Specifically, the present invention relates to assays for measuring the potency, specificity and toxicity of hPGDS inhibitors.